First patient dosed with dalbavancin in S. aureus bacteremia trial
The trial will assess the efficacy of a two week…
The trial will assess the efficacy of a two week regimen of the FDA-approved antibiotic dalbavancin in treating 100 patients with Staphylococcus aureus bacteremia.